



# THE POWER OF PRECISION FOR EVERY ONCOLOGIST TODAY

INTERIM REPORT H1 2024

**2curex**

# HIGHLIGHTS AND KEY FIGURES

## A new path

The first half of 2024 was transformative for 2cureX, marked by strategic leadership changes and a decisive pivot in our business model. Despite challenges, the company embraced new opportunities, restructuring into two focused entities. Publicly listed 2cureX AB will drive a fresh Direct-to-Patient strategy and explore technology acquisitions, while privately held 2cureX A/S will concentrate on advancing product development. This innovative approach has secured significant financing and positioning us for growth in Functional Precision Oncology. We are confident that these changes will enhance patient outcomes, accelerate value creation, and deliver long-term benefits to our shareholders.

Since its IPO in 2017, 2cureX has operated as a holding company with subsidiaries in Denmark and Germany. In June 2024, 2cureX AB took a major step forward by issuing 7 500 000 new shares to an investment consortium led by the Kinled Group. This, along with a €3 million loan, will fuel 2cureX AB's growth in Functional Precision Oncology. A key strategic shift followed with the sale of its Danish subsidiary, 2cureX A/S, though both entities will maintain a collaborative partnership. These actions reflect 2cureX's commitment to advancing cancer treatment through innovative functional approaches, positioning the company for future success.

With this significant restructuring 2cureX can address the challenges in commercializing IndiTreat®. The split into two independent entities ensures that 2cureX AB remains publicly listed and focusing on a robust commercial strategy to become a leader in Functional Precision Oncology by expanding direct-to-patient offerings. 2cureX A/S, operating privately, will drive product development, including CE-IVDR certification and new cancer tests. The two entities will collaborate closely, combining commercial and innovation efforts. Additionally, the Board of Directors will expand, bringing expertise in direct-to-patient business models to strengthen 2cureX AB's growth strategy.

## Financial Overview

The issuing of 7 500 000 new shares has been paid in full in August 2024, with a total of 2 690 KSEK, and the sale of 2cureX A/S has been executed with full payment of 5 617 KSEK, also received in August 2024. This, together with the €3 million loan has secured the path forward and ensured the funds to keep the operations going forward.

(KSEK)	H1 2024 1/1 - 30/06	H1 2023 1/1 - 30/06	2023 1/1 - 31/12	2022 1/1 - 31/12
Net sales	0	80	155	90
Other operating income	500	1 391	2 792	3 279
Profit before tax	-9 560	-15 729	-25 892	-29 770
Earnings per share (SEK)*	-0.54	-0.89	-1.72	-1,69
Equity ratio**	40%	92%	82%	90%
Cash and bank	3 130	26 293	13 403	44 894
Average number of shares	17 602 916	17 602 916	17 602 916	17 580 961
No. of shares by the end of the period	17 602 916	17 602 916	17 602 916	17 602 916

\*Earnings per share: Profit for the period divided by the average number of shares.

\*\*Equity ratio: Shareholder's equity divided by total capital.

## January

- 2CUREX ANNOUNCES CHANGES TO THE BOARD OF DIRECTORS.

The exiting members, Povl-Andre' Bendz, Camilla Huse Bondesson, Michael Schaeffer, and Michel Klimkeit, are concluding their lengthy service on the Board

## February

- NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)
- 2CUREX PUBLISHES INTERIM REPORT FOR THE FOURTH QUARTER AND FULL YEAR OF 2023 AND FINANCIAL AND STRATEGIC OUTLOOK FOR 2024
- BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)

Shareholders in the company propose that the extraordinary general meeting elect a new member of the Board of Directors

Election of Grith Hagel as a new board member. Part of a strategic initiative as 2cureX refines its strategy to facilitate the implementation of IndiTreat® testing across individual hospitals.

## March

- 2CUREX AB (PUBL) PROVIDES AN UPDATE ON ITS FINANCIAL POSITION AND CURRENT OPERATIONS

The business model failed to deliver the forecasted revenue, and it was decided to change the business model to decentralized testing at individual hospitals

## May

- 2CUREX AB (PUBL) HAS DECIDED TO APPLY FOR A DELISTING OF ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET IN STOCKHOLM – EXPECTED LAST DAY OF TRADING BY END OF JUNE
- REVISED FINANCIAL CALENDAR ANNOUNCEMENT
- NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (PUBL)

The Board of Directors of 2cureX has resolved to proceed with a formal delisting application.

2cureX will limit the number of quarterly reports for Q2 and Q4.

## June

- 2CUREX AB ABORTS DELISTING AND ANNOUNCES DIRECTED SHARE ISSUE TO A PRIVATE INVESTMENT COMPANY AND SALE OF THE SUBSIDIARY 2CUREX A/S
- 2CUREX APPOINTS OLE THASTRUP AS NEW CEO
- EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)
- RELEASE OF THE 2CUREX AB (PUBL) ANNUAL REPORT

The Directed Issue will be made to a consortium led by Kinled Group (<http://www.kinled.com>). In addition, the Company has secured a loan of 3 million EUR from the consortium to further develop 2cureX AB

## AFTER REPORTING PERIOD

## July

- KOMMUNIKÉ FRÅN ÅRSSTÄMMAN I 2CUREX AB (PUBL)
- KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Beslutades all att sälja det danska dotterbolaget 2cureX A/S.

# PERIOD OF SIGNIFICANT CHANGE

The first half of 2024 has been one of the most transformative periods in 2cureX's history. The year began with significant leadership changes, including the departure of our CEO and two-thirds of the Board of Directors. Additionally, we made the difficult decision to halt our commercialization efforts.

The Distributor-led commercial model we had previously adopted failed to deliver the expected number of patient samples and the associated revenue, leading to a substantial decline in our share price. As a result, a meaningful market-based financing option was no longer feasible.

## Public listing and private entity

In response, the Management and Board of Directors explored the possibility of delisting 2cureX from Nasdaq First North Growth Market, with the intention of securing private market funding.

During this period, we were approached by an investment consortium led by the Kinled Group, a Hong Kong-based private investment firm with a 30-year history in life sciences. Negotiations led to an innovative arrangement in which the 2cureX Group was divided into two independent entities: a publicly listed 2cureX AB and a privately held 2cureX A/S. This transaction secured financing for 2cureX AB through a directed issue of 7 500 000 newly issued shares and a loan facility of 3 million EUR.

## Two Distinct Business Models

The newly structured 2cureX AB will focus on a fresh commercial strategy, specifically a Direct-to-Patient offering for IndiTreat®. Additionally, it will seek to acquire other technologies within the Functional Precision Oncology space. Meanwhile, the private 2cureX A/S will concentrate on product development, particularly the delivery of a CE-IVDR certified IndiTreat® testing platform that can be implemented at individual hospitals.

Both companies will establish a strategic partnership, with the Board of Directors of 2cureX AB expected to expand from three to five members.

## Creating Shareholder Value

The past period has been challenging for our shareholders, marked by a significant and prolonged drop in share price. However, we believe that the new structure of 2cureX will reverse this trend. Through synergy, we aim to advance Functional Precision Oncology by integrating IndiTreat® testing into daily clinical practice, ultimately improving patient outcomes and accelerating value creation for our shareholders.

Over the past few years, it has become evident that Functional Precision Oncology is gaining significant traction among leading clinical researchers at major hospitals across Europe and the US. Since the success of the first prospective, interventional clinical trial where the 3D microtumor test, IndiTreat® effectively guided the treatment of patients with advanced cancer, approximately 800 clinical trials worldwide are now utilizing these Functional Precision Oncology tools for treatment design. 2cureX is uniquely positioned to capitalize on this emerging trend in cancer treatment.

We deeply appreciate the ongoing support from our shareholders during these challenging times and are committed to delivering value that benefits both cancer patients and our investors.



**Ole Thastrup, CEO & Founder**

August 22, 2024

# WHAT TO EXPECT GOING FORWARD

## Current Structure and Strategic Evolution

As of now, 2cureX's activities are bifurcated into two primary areas: product development and the commercialization of IndiTreat®. The company has encountered significant challenges in commercializing a novel diagnostic product that is not yet publicly reimbursed, particularly through a distributor-led model. Recognizing these obstacles, the Board of Directors (BoD) proposed, and received approval from both the Annual General Meeting 2024 and an Extraordinary General Meeting on July 12, to restructure 2cureX into two independent entities: 2cureX AB and 2cureX A/S.

## Organizational Restructuring and Strategic Focus

- 2cureX AB: This entity will continue as a publicly listed company on the Nasdaq First North Growth Market, focusing on a dedicated commercial business model. The primary objective for 2cureX AB is to establish itself as a global leader in Functional Precision Oncology. This will be achieved through a robust commercial strategy aimed at expanding the reach of IndiTreat® tests directly to patients.
- 2cureX A/S: Operating as a private company funded by private equity, 2cureX A/S will concentrate on product development. This includes the CE-IVDR certification of IndiTreat®, automation of the testing process, and expansion into additional cancer types. By narrowing its focus, 2cureX A/S aims to accelerate innovation and streamline product development processes.

The two entities will maintain a strategic partnership wherein 2cureX AB will leverage its commercial capabilities to bring IndiTreat® tests directly to patients, while 2cureX A/S will continue to innovate and expand the product portfolio.



[www.inditreat.com](http://www.inditreat.com)

# CONSTRUCTION OF THE NEW 2CUREX

## Original corporate structure

Since its IPO in November 2017, the 2cureX group has been structured as a holding company, 2cureX AB, listed on the Nasdaq First North Growth Market, alongside two operational subsidiaries: 2cureX A/S (Denmark) and 2cureX GmbH (Germany). 2cureX A/S has been responsible for developing, owning, and operating the IndiTreat® technology, while 2cureX GmbH has managed partnerships in Germany.

## Strategic Restructuring and Investment

On June 17, 2024, 2cureX AB announced a significant strategic move by executing a directed issue of 7,500,000 new shares. This issuance was directed to an investment consortium led by Kinled Group, a Hong Kong-based private investment firm with a 30-year track record in life sciences. Alongside this equity investment, the company secured a loan of 3 million EUR from the consortium, which will be utilized to further develop 2cureX AB's operations in the burgeoning field of **Functional Precision Oncology**. This development aligns with a revised commercial business strategy that the company is currently implementing (details of which can be found on page X of this report).

In a further strategic shift, an Extraordinary General Meeting (EGM) held on July 12, 2024, resulted in the decision to sell 2cureX AB's Danish subsidiary, 2cureX A/S, to a consortium composed of existing 2cureX AB shareholders and the Kinled Group. Despite this separation, 2cureX AB and 2cureX A/S plan to collaborate closely as independent entities, forging a strategic partnership to ensure the global availability of the IndiTreat® test for cancer patients.


## Challenges in Distributor-Based Commercialization

Beginning in late 2023, it became evident to the Board of Directors that the commercialization model chosen for the IndiTreat® test was underperforming in terms of revenue expectations. The initial strategy involved establishing an extensive network of distributors across Europe to market the CE-IVD approved IndiTreat® tests to cancer hospitals in their respective regions. Patient samples collected from these hospitals were then sent to 2cureX's central testing facility in Copenhagen, Denmark, for drug-sensitivity testing.

This distributor-based model facilitated a rapid rollout to over 250 hospitals across Europe. While this increased the awareness of IndiTreat®'s potential to predict effective treatments for advanced colorectal cancer, it faced significant hurdles. The primary challenge was that the expected revenue from these efforts did not materialize, largely due to the difficulties associated with commercializing products that had yet to receive widespread reimbursement.

## Revitalization and Future Direction of 2cureX AB

The recent acquisition of 7 500 000 shares by the Kinled Group has resulted in the group holding a 29% stake in 2cureX AB. This investment not only strengthens the company's financial position but also signals a shift in governance. As a result, the Board of Directors of 2cureX AB will propose at an upcoming Extraordinary General Meeting to expand the Board from three to five members.



2cureX is located at  
Symbion Research Park,  
Copenhagen

# DEVELOPMENTS DURING H1 2024, IN FIGURES

Numbers within parentheses refer to the corresponding period in the preceding year. For additional information about 2cureX's financial position and development, please refer to the Company's website ([www.2cureX.com](http://www.2cureX.com)).

## Net sales and operating income

Net sales for H1 2024 amounted to 0 KSEK (67 KSEK). Other operating income for H1 2024 amounted to 500 KSEK (610 KSEK).

## Financial development

The result during H1 2024 amounted to -9 558 KSEK (-15 730KSEK). The result for the period has been impacted by the restructuring of the Group's activities and reduced operational costs.

## Liquidity

The Group's cash and cash equivalents amounted to 3 130 KSEK (26 293 KSEK) as of June 30, 2024. Cash flow during H1 2024 amounted to -10 560 KSEK (-19 201 KSEK). Cash flow from operating activities in H1 2024 amounted to -10 560 KSEK (-19 190 KSEK).

## Solidity

The Group's equity ratio as of June 30, 2024 amounted to 40 percent (92).

## The share

There is one class of shares in 2cureX AB (publ). The Company's share is listed on Nasdaq First North Growth Market under the ticker "2CUREX". As of June 30, 2024, the number of shares amounted to 17 602 916 (17 602 916).

The average number of shares in H1 2024 amounted to 17 602 916 (17 602 916).

## Warrant program for employees and board members

The Annual General Meeting on May 27, 2021 established a Series 2021/24 warrant program for the Group's CEO totaling 700 000 warrants. Today this carries the right to subscribe for newly issued shares in 2cureX AB in the period April 1, 2024, to June 30, 2024 (233 334 warrants).

The extra general meeting on August 8, 2022, resolved to establish a warrant program for a new board member. The warrant program totaling 40 000 warrants carry the right to subscribe for newly issued shares in 2cureX AB in the period from August 8, 2026, up to and including October 31, 2026. Each subscription warrant entitles the holder to subscribe for 1 share, at a subscription price equal to 110 percent of the volume weighted average price at Nasdaq First North Growth Market during a period of ten trading days following the extra general meeting on August 8, 2022. Upon full exercise of the issued warrants, the share capital would increase by 4 KSEK. The warrants will be subject to the usual conversion terms in connection with new share issues etc.

## Subsequent events

2cureX AB received payment for the increase in the share capital in August 2024, which totals 2 691 KSEK for the emission of 7 000 000 new shares. 2cureX AB also received payment for the sale of 2cureX A/S, which totals 5 616 KSEK in August 2024.

## Policies for the preparation of the interim financial report

2cureX AB applies the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3) in the preparation of its financial reports.

## Auditors' review

This interim report has not been reviewed by the Company's auditors

# CORPORATE GOVERNANCE

The 2cureX group consists of a holding company, 2cureX AB (publ) (Sweden) that is listed at Nasdaq First North Growth Market, and two operational companies 2cureX A/S (Denmark) and 2cureX GmbH (Germany). 2cureX AB and 2cureX A/S have the same Board of Directors who has the overall responsibility of the governance structure for the 2cureX group.

Corporate governance is linked to compliance with Nasdaq First North Growth Market Rulebook and laws and regulations relevant for 2cureX.

Key aspects of the governance structure relate to shareholder's meetings, Article of Association, the composition of the Board of Directors and Board's annual wheel. The board of Directors has implemented relevant policies and procedures for 2cureX.





## BOARD OF DIRECTORS



**TONNI BÜLOW-NIELSEN**  
Chairman of 2cureX AB and  
2cureX A/S



**OLE THASTRUP**  
Vice Chairman and Founder of  
2cureX AB and 2cureX A/S




**GRITH HAGEL**  
Board Member and Founder of  
2cureX AB and 2cureX A/S

## CLINICAL ADVISORY BOARD



**DR. JOHN L. MARSHALL**  
MD is Chief, Hematology and  
Oncology at Georgetown  
University Hospital, and Professor  
of Medicine and Oncology  
at Georgetown University in  
Washington D.C.



**DR. JESUS GARCIA- FONCILLAS**  
MD PhD is currently the Director  
of the University Cancer  
Institute and the Department  
of Oncology at the University  
Hospital "Fundacion Jimenez  
Diaz" in Spain.



**DR. ANDREW BEGGS**  
is currently Professor of Cancer  
Genetics & Surgery at the  
Institute of Cancer and Genomic  
Sciences and Co- Lead of  
Molecular Oncology, Pathology  
and Genetics, University of  
Birmingham, UK.

# MANAGEMENT



**OLE THASTRUP**  
CEO



**GRITH HAGEL**  
VP Innovation and Founder



**KENNETH G. JOHANSEN**  
CFO



**JACOB THASTRUP**  
CTO



**MANUEL FERNANDEZ**  
Director Quality & Regulatory



**ROSITA KAAE**  
Director Business Development

# FINANCIAL CALENDAR

The Company prepares and publishes a financial report for each fiscal quarter. Upcoming reports are planned to be released as follows:

- |  |           |
|--|-----------|
| • Interim Report H2 2024<br>(Full year 2024) | 27/2-2025 |
| • Annual report 2024                         | 24/4-2025 |
| • Annual General Meeting, 2025               | 22/5-2025 |
| • Interim Report H1, 2025                    | 21/8-2025 |



# DELIVERY OF INTERIM REPORT

Landskrona, August 22, 2024 2cureX AB

## BOARD OF DIRECTORS

---

**TONNI BÜLOW-NIELSEN**

*Chairman of the Board*

---

**OLE THASTRUP**

*Vice Chairman and Founder*

---

**GRITH HAGEL**

*Board Member and Founder*

**CERTIFIED ADVISER**

Redeye AB

# FINANCIAL OVERVIEW



# FINANCIAL OVERVIEW

## THE GROUP

<b>SUMMARY OF INCOME STATEMENT – THE GROUP</b> (KSEK)	<b>H1 2024</b> 1/1-30/06	<b>H1 2023</b> 1/1-30/06	<b>2023</b> 1/1-31/12	<b>2022</b> 1/1-31/12
<b>Operating income</b>				
Net sales	0	80	155	90
Other operating income	500	1 391	2 792	3 279
<b>Total operating income</b>	<b>500</b>	<b>1 471</b>	<b>2 947</b>	<b>3 369</b>
<b>Operating expenses</b>				
Other external expenses	-2 922	-5 533	-10 834	-12 384
Personnel costs	-7 097	-12 891	-26 496	-22 807
Depreciation of tangible fixed assets	-103	-174	-312	-311
<b>Total operating expenses</b>	<b>-10 122</b>	<b>-18 598</b>	<b>-37 642</b>	<b>-35 502</b>
<b>Operating profit</b>	<b>-9 622</b>	<b>-17 127</b>	<b>-34 695</b>	<b>-32 133</b>
Financial posts	62	1 398	-753	2 363
<b>Profit before tax</b>	<b>-9 560</b>	<b>-15 729</b>	<b>-35 448</b>	<b>-29 770</b>
Tax <sup>1</sup>	2	-1	4 629	0
<b>The result of the period</b>	<b>-9 558</b>	<b>-15 730</b>	<b>-30 819</b>	<b>-29 770</b>
Earnings per share (SEK)	-0,54	-0.89	-1.72	-1.69
Average number of shares	17 602 916	17 602 916	17 602 916	17 580 961
No. of shares at the end of the period	17 602 916	17 602 916	17 602 916	17 602 916

<sup>1)</sup> This post refers to tax relief in subsidiaries regarding R&D work.

<b>SUMMARY OF BALANCE SHEET</b>	2024	2023
<b>– THE GROUP (KSEK)</b>	1/1-30/06	1/1-30/06
<b>Assets</b>		
<b>Fixed assets</b>		
Tangible fixed assets	608	877
<b>Total fixed assets</b>	<b>608</b>	<b>877</b>
<b>Current assets</b>		
Receivables	3 311	255
Cash and bank balances	3 129	26 293
<b>Total current assets</b>	<b>6 441</b>	<b>28 888</b>
<b>Total assets</b>	<b>7 049</b>	<b>29 765</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
Share capital	1 760	1 760
Ongoing share issue		0
Other contributed capital	107 664	107 664
Other equity	-97 081	-70 532
The result of the period	-9 558	-15 730
<b>Total equity</b>	<b>2 785</b>	<b>27 362</b>
<b>Current liabilities</b>		
Short-term liabilities 2)	4 264	2 403
<b>Total short-term liabilities</b>	<b>4 264</b>	<b>2 403</b>
<b>Total equity and liabilities</b>	<b>7 049</b>	<b>29 765</b>

<b>SUMMARY OF CASH FLOW –</b>	H1 2024	H1 2023	2023	2022
<b>THE GROUP (KSEK)</b>	1/1-30/06	1/1-30/06	1/1-31/12	1/1-31/12
Cash flow from operating activities	-10 560	-19 190	-32 447	-27 984
Cash flow from investment activities	0	-11	-19	-541
Cash flow from financing activities	0	0	0	0
<b>Cash flow for the period</b>	<b>-10 560</b>	<b>-19 201</b>	<b>-32 466</b>	<b>-28 525</b>
Cash and cash equivalents at the beginning of the period	13 403	44 894	44 894	72 942
Exchange rate difference in cash and cash equivalents	287	600	975	477
<b>Cash and cash equivalents at the end of the period</b>	<b>3 130</b>	<b>26 293</b>	<b>13 403</b>	<b>44 894</b>

**CHANGE OF EQUITY – THE GROUP**  
 1/1-2024 - 30/06 2024

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
<b>At the beginning of the period (1/1-2024)</b>	<b>1 760</b>	<b>0</b>	<b>107 664</b>	<b>-64 828</b>	<b>-32 518</b>	<b>12 078</b>
Outline of previous year's results				-32 518	32 518	
Rights issue						
Issue cost						
Issues of shares						
Rights issue						
Translation difference					265	265
The result of the period					-9 558	-9 558
<b>At the end of the period (30/6-2024)</b>	<b>1 760</b>		<b>107 664</b>	<b>-97 346</b>	<b>-9 558</b>	<b>2 785</b>

## 1/1-2023 – 30/06 2023

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
<b>At the beginning of the period (1/1-2023)</b>	<b>1 760</b>	<b>0</b>	<b>107 664</b>	<b>-36 620</b>	<b>-29 770</b>	<b>43 034</b>
Outline of previous year's results				-29 770	29 770	0
Translation difference				1 019		1 019
Rights Issue				543		543
The result of the period					-32 518	-35 518
<b>At the end of the period (30/06-2023)</b>	<b>1 760</b>	<b>0</b>	<b>107 664</b>	<b>-64 828</b>	<b>-32 518</b>	<b>12 078</b>



# FINANCIAL OVERVIEW

## PARENT COMPANY

SUMMARY OF INCOME STATEMENT – PARENT COMPANY (KSEK)	H1 2024 1/1-30/06	H1 2023 1/1-30/06	2023 1/1-31/12	2022 1/1-31/12
<b>Operating income</b>				
Net sales	0	0	0	0
<b>Total operating income</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Operating expenses</b>				
Other external expenses	-519	-736	-1 786	-1 796
Staff costs	-359	-378	-1 042	-1 209
<b>Total operating expenses</b>		<b>-1 114</b>	<b>-2 828</b>	<b>-3 005</b>
<b>Operating profit</b>	<b>-878</b>	<b>-1 114</b>	<b>-2 828</b>	<b>-3 005</b>
Financial posts	-1	-132	357	-50 491
<b>Profit before tax</b>	<b>-879</b>	<b>-1 246</b>	<b>-2 471</b>	<b>-53 496</b>
Tax	0	0	0	0
<b>The result of the period</b>	<b>-879</b>	<b>-1 246</b>	<b>-2 471</b>	<b>-53 496</b>

SUMMARY OF BALANCE SHEET – PARENT COMPANY (KSEK)	2024 1/1-30/06	2023 1/1-30/06
<b>Assets</b>		
<b>Fixed assets</b>		
Financial assets	5 000	31 329
<b>Total fixed assets</b>	<b>5 000</b>	<b>31 329</b>
<b>Current assets</b>		
Receivables	210	168
Cash and bank balances	1 474	12 494
<b>Total current assets</b>	<b>1 684</b>	<b>12 662</b>
<b>Total assets</b>	<b>6 684</b>	<b>43 891</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
Share capital	1 760	1 760
Premium fund	111 864	111 864
Ongoing share issue	0	0
Balanced result	-107 088	-68 894
The result of the period	-879	-1 246
<b>Total equity</b>	<b>5 658</b>	<b>43 484</b>
<b>Current liabilities</b>		
Current liabilities	1 026	454
<b>Total short-term liabilities</b>	<b>1 026</b>	<b>454</b>
<b>Total equity and liabilities</b>	<b>6 684</b>	<b>48 891</b>

<b>SUMMARY OF CASH FLOW – PARENT COMPANY (KSEK)</b>	<b>H1 2024</b> 1/1-30/06	<b>H1 2023</b> 1/1-30/06	<b>2023</b> 1/1-31/12	<b>2022</b> 1/1-31/12
Cash flow from operating activities	-635	-592	-1 952	-1 936
Cash flow from investment activities	0	-26 229	-35 904	-20 000
Cash flow from financing activities	650	0	0	0
<b>Cash flow for the period</b>	<b>15</b>	<b>-26 821</b>	<b>-37 856</b>	<b>-21 936</b>
Cash and cash equivalents at the beginning of the period	1 459	39 315	39 315	67 176
<b>Cash and cash equivalents at the end of the period</b>	<b>1 474</b>	<b>12 494</b>	<b>1 459</b>	<b>45 240</b>

**CHANGE OF EQUITY – PARENT COMPANY**

1/1-2024 - 30/06 2024

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
<b>At the beginning of the period (1/1-2024)</b>	<b>1760</b>	<b>0</b>	<b>111 864</b>	<b>-68 711</b>	<b>-38 376</b>	<b>6 537</b>
Outline of previous year's results				-38 376	38 376	0
Allocation of staff warrants						
Issue cost						
Rights issue						
Ongoing share issue						
The result of the period					-879	-879
<b>At the end of the period (30/9-2023)</b>	<b>1760</b>	<b>0</b>	<b>111 864</b>	<b>-10 7087</b>	<b>-879</b>	<b>5 658</b>

1/1 2023 – 30/06 2023

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
<b>At the beginning of the period (1/1 2023)</b>	<b>1760</b>	<b>0</b>	<b>111 864</b>	<b>-15 758</b>	<b>-53 496</b>	<b>44 370</b>
Outline of previous year's results				-53 496	53 496	0
Allocation of staff warrants				543		543
Registration of share issue						0
The result of the period					-38 376	-38 376
<b>At the end of the period (30/06 2023)</b>	<b>1760</b>	<b>0</b>	<b>111 864</b>	<b>-68 711</b>	<b>-38 376</b>	<b>6 537</b>

# THE POWER OF PRECISION FOR EVERY ONCOLOGIST TODAY

**2cureXAB** (publ)

Corporate registration number: 559128-0077

**2cureX A/S**

Fruebjergvej 3 / DK-2100 Copenhagen / Denmark  
Phone: +45 2211 5399 / E-mail: info@2curex.com